Unicycive Therapeutics, Inc. (UNCY)

$0.5284

-0.00 (-0.30%)
Rating:
Recommendation:
-
Symbol UNCY
Price $0.5284
Beta 2.627
Volume Avg. 0.05M
Market Cap 18.364M
Shares () -
52 Week Range 0.4-2.87
1y Target Est -
DCF Unlevered UNCY DCF ->
DCF Levered UNCY LDCF ->
ROE -762.51% Strong Sell
ROA -199.19% Strong Sell
Operating Margin -
Debt / Equity 25.22% Neutral
P/E -0.36 Neutral
P/B 5.02 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest UNCY news


Dr. Shalabh K. Gupta M.D., MPA
Healthcare
Biotechnology
NASDAQ Capital Market

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.